Company / Operating Cash Flow
Eloxx Pharmaceuticals, Inc. Operating Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$14.3M
FY2025
5-year range
-$14.3M / -$3.9M
FY2021-FY2025
Trend
-194.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$4M to -$14M over the past 10 years.
Based on SEC 10-K filings.
-$14M in FY2025.
Declined from -$4M to -$14M over the past 10 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 194.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$14.3M | -194.6% |
| FY2016 | -$4.9M | -24.7% |
| FY2015 | -$3.9M | +11.0% |
| FY2014 | -$4.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026